Losartan Global Regulatory Status: FDA Approval, Label Requirements, and Post-Market Safety

When and Why the FDA Approved Losartan

The FDA approved losartan potassium (Cozaar, Merck Sharp and Dohme) on April 14, 1995, making it the first ARB to reach the US market. The approval was based on controlled clinical trials demonstrating blood pressure reduction across a broad adult population, including patients who could not tolerate ACE inhibitors because of cough. The agency later expanded the label twice: once for diabetic nephropathy and once for stroke risk reduction in hypertensive patients with left ventricular hypertrophy (LVH). [1]

Original NDA and the Path to Approval

NDA 020386 was submitted under the standard review pathway. Merck's key data showed losartan 50-100 mg once daily reduced sitting diastolic blood pressure by 5.5 to 10.5 mmHg versus placebo across multiple Phase III trials. The drug's selectivity for the AT1 receptor distinguished it mechanistically from ACE inhibitors, and the absence of bradykinin accumulation explained the lower cough rate that became a major commercial and clinical differentiator. The full Drugs@FDA record for NDA 020386 remains publicly accessible. [1]

Subsequent Label Expansions

The diabetic nephropathy indication was added based on the RENAAL trial (N=1,513), published in 2001, which showed losartan 50-100 mg reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% versus placebo in patients with type 2 diabetes and nephropathy (P<0.02). [2]

The stroke-reduction indication followed the LIFE trial (Lancet 2002, N=9,193), a randomized, double-blind study comparing losartan-based therapy with atenolol-based therapy in hypertensive patients with electrocardiographic LVH. Losartan reduced the primary composite endpoint (cardiovascular death, stroke, or myocardial infarction) by 13% and stroke specifically by 25%, both at similar achieved blood pressures. [3] The FDA accepted these data as the basis for a new indication label.

What the Current FDA Prescribing Label Requires

The current losartan label specifies three approved adult indications, mandatory contraindications, a boxed warning, and specific dosing tables for renal and hepatic impairment. Clinicians prescribing any formulation, branded or generic, are legally bound to this label under 21 CFR part 201. [4]

Boxed Warning: Fetal Toxicity

The label carries a black box warning stating that drugs acting on the renin-angiotensin system can cause fetal injury and death when administered to pregnant women during the second or third trimester. This warning was strengthened following post-market case reports and preclinical data. Prescribers must counsel all patients of reproductive potential, and losartan should be discontinued as soon as pregnancy is detected. [4]

The FDA's own guidance on REMS and labeling updates for renin-angiotensin-aldosterone system (RAAS) drugs, including ARBs, is maintained at accessdata.fda.gov. [4]

Dosing and Titration Requirements

The label recommends 50 mg once daily as the starting dose for most adults, titrated to 100 mg once daily if additional blood pressure lowering is needed. For patients with possible volume depletion or hepatic impairment, the starting dose is 25 mg once daily. No dose adjustment is specified for renal impairment alone, though the label advises monitoring in patients with severe renal insufficiency. [4]

Drug Interactions Listed on Label

Clinically meaningful interactions flagged in the label include:

• NSAIDs: may attenuate the antihypertensive effect and acutely worsen renal function, particularly in older patients or those with pre-existing kidney disease.
• Potassium-sparing diuretics or potassium supplements: risk of hyperkalemia, especially with concomitant ACE inhibitor or in diabetic patients.
• Lithium: ARBs reduce lithium clearance; lithium toxicity has been reported.
• Dual RAAS blockade: the label explicitly discourages combining losartan with aliskiren in patients with diabetes or renal impairment (eGFR <60 mL/min/1.73 m²) based on ONTARGET/ALTITUDE data. [4]

Losartan on the WHO Essential Medicines List

The World Health Organization added losartan to its Model List of Essential Medicines in 2019, in the category of medicines for cardiovascular diseases. [5] The decision reflected the global burden of hypertension (estimated at 1.28 billion adults as of 2021 per WHO data) and the drug's patent expiry, which had made low-cost generic production viable in low- and middle-income countries. [5]

Inclusion on the EML is not a regulatory approval in itself, but it signals WHO's determination that benefit-risk is favorable at the population level. Many national formulary committees in Africa, Southeast Asia, and Latin America use EML status as a precondition for national listing.

EMA Approval and European Regulatory Status

Originator Authorization and Generics

The European Medicines Agency authorized Cozaar through a centralized procedure; the originator authorization has since expired with the patent. As of 2024, the EMA's medicines database lists multiple generic losartan potassium 12.5 mg, 25 mg, 50 mg, and 100 mg film-coated tablet products authorized across EU member states through both centralized and mutual recognition procedures. [6]

EMA Pharmacovigilance Actions

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed losartan-containing products as part of the broader ARB class review triggered by the 2018 NDMA contamination findings. PRAC issued recommendations requiring manufacturers to review and validate their active pharmaceutical ingredient (API) synthesis routes and to test final products for nitrosamine impurities. [6] This review process is described in further detail below.

The 2018-2019 NDMA and NDEA Contamination Recalls

What Triggered the Recalls

In 2018, the FDA and EMA identified N-nitrosodimethylamine (NDMA) in valsartan API manufactured by Zhejiang Huahai Pharmaceutical. The investigation subsequently expanded to losartan API from multiple manufacturers. By mid-2019, the FDA had posted more than 40 separate losartan recall notices, covering tablets from manufacturers including Torrent Pharmaceuticals, Sun Pharmaceutical Industries, and Sandoz. [7]

NDMA and N-nitrosodiethylamine (NDEA) are probable human carcinogens classified as Group 2A and Group 2B by the International Agency for Research on Cancer. The FDA set an acceptable daily intake limit of 96 nanograms per day for NDMA in drug products. [7]

Regulatory Response

The FDA issued interim limits and required all manufacturers of sartan-class drugs to test finished products and APIs using validated methods, including liquid chromatography-mass spectrometry (LC-MS). The agency published detailed guidance for industry on controlling nitrosamine impurities in human drugs. [7]

Prescribers were advised not to instruct patients to stop their ARB therapy abruptly; uncontrolled hypertension carries a more immediate risk than the incremental cancer risk from short-term NDMA exposure. The FDA's recall database and updated guidance remain available at fda.gov. [7]

The table below summarizes the regulatory response timeline:

| Year | Regulatory Action | |------|------------------| | July 2018 | FDA and EMA alert: NDMA found in valsartan API (Zhejiang Huahai) | | November 2018 | FDA expands review to all sartan APIs; losartan included | | March-August 2019 | FDA issues 40+ losartan recall notices across multiple manufacturers | | 2020-present | FDA requires nitrosamine risk assessments for all drug products per guidance |

Post-Market Safety: What the Evidence Shows After Approval

Cardiovascular Outcomes: LIFE Trial Data

The LIFE trial (Lancet 2002, N=9,193) remains the most cited outcomes study for losartan. Patients with hypertension and LVH were randomized to losartan-based or atenolol-based regimens and followed for a mean of 4.8 years. The losartan group achieved a 13% relative risk reduction in the primary composite endpoint (cardiovascular death, stroke, or MI) with a hazard ratio of 0.87 (95% CI 0.77-0.98, P<0.021), driven largely by a 25% reduction in fatal and nonfatal stroke. [3]

The trial's authors, Dahlof et al., wrote: "Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure, and is better tolerated." [3] This finding directly supported the FDA's decision to add stroke risk reduction as a labeled indication.

Renal Protection: RENAAL Data

In the RENAAL trial (N=1,513), Brenner et al. Reported that losartan reduced the risk of a doubling of serum creatinine by 25% and end-stage renal disease by 28% versus placebo, both P<0.01, in patients with type 2 diabetes and nephropathy. [2] Mean follow-up was 3.4 years. These data anchored the diabetic nephropathy indication and are cited in multiple nephrology society guidelines.

Long-Term Safety Signals from Sentinel

The FDA's Sentinel System, which analyzes real-world electronic health records and claims data from over 100 million patients, has been used to evaluate ARB class safety signals post-market. [8] Published analyses have not identified unexpected cardiovascular or oncologic signals for losartan beyond those described in the label, with the exception of the nitrosamine contamination episode described above.

Hyperkalemia Risk in High-Risk Populations

One consistent post-market finding is the risk of clinically significant hyperkalemia when losartan is combined with aldosterone antagonists, ACE inhibitors, or potassium supplements in patients with CKD or diabetes. A 2012 meta-analysis in the BMJ (ONTARGET substudy, N=25,620) found that dual RAAS blockade doubled the risk of hyperkalemia requiring hospitalization compared with monotherapy. [9] The current label addresses this, but real-world prescribing data suggest co-prescribing remains common.

Generic Availability and Bioequivalence Standards

ANDA Field in the United States

Following Merck's patent expiry, the FDA has approved dozens of abbreviated new drug applications (ANDAs) for losartan potassium tablets in 25 mg, 50 mg, and 100 mg strengths. Generic manufacturers must demonstrate bioequivalence to Cozaar per FDA's standard bioequivalence criteria: the 90% confidence interval for the geometric mean ratio of AUC and Cmax must fall within 80-125% of the reference listed drug. [10]

The FDA's Orange Book lists losartan potassium under therapeutic equivalence code AB, meaning rated generics are considered therapeutically equivalent to the reference listed drug and may be substituted by pharmacists in most US states. [10]

International Generic Approvals

Outside the US, losartan generics are approved by Health Canada, the Therapeutic Goods Administration (TGA) in Australia, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and multiple national regulators across the EU under mutual recognition. The WHO Prequalification Programme has also prequalified select generic losartan products for use in low- and middle-income country procurement programs. [5]

Special Populations: Label Guidance and Regulatory Restrictions

Pregnancy

The boxed warning prohibits use in the second and third trimesters. First-trimester use carries a lower but non-zero risk; the label advises switching to an alternative antihypertensive as soon as pregnancy is confirmed. The FDA classifies losartan as Pregnancy Category D based on post-marketing reports of fetal renal dysplasia, oligohydramnios, and neonatal renal failure. [4]

Pediatric Patients

The FDA approved a pediatric indication for losartan in hypertension for children aged 6 years and older, supported by pharmacokinetic and efficacy data. The label provides weight-based dosing: children 20-50 kg may start at 25 mg daily; children above 50 kg may start at 50 mg daily. [4] Use in children with a glomerular filtration rate <30 mL/min/1.73 m² is not recommended due to insufficient data.

Hepatic Impairment

Patients with a history of hepatic impairment should start at 25 mg once daily. Losartan undergoes significant first-pass metabolism in the liver, and its active metabolite EXP3174 is generated via CYP2C9. In patients with moderate hepatic impairment, AUC for losartan increases approximately 5-fold compared with healthy subjects. [4]

What Clinicians Should Know in 2024: A Practical Regulatory Summary

Losartan's regulatory record across nearly three decades reflects a drug with a stable efficacy profile, a well-characterized safety record, and two significant post-market events (the renal protection label expansion and the 2018-2019 nitrosamine contamination crisis) that both produced constructive regulatory action rather than market withdrawal.

The FDA label is the controlling document for US prescribers. The three approved indications, the fetal toxicity boxed warning, the potassium monitoring requirements, and the RAAS-combination restrictions are not suggestions. They are labeling requirements enforceable under federal law.

For patients currently stable on a generic losartan product, the recall period has passed, and supply chain nitrosamine testing protocols are now in place. Patients should not discontinue losartan without physician guidance; the cardiovascular risk of uncontrolled hypertension over days to weeks exceeds the actuarial cancer risk from historical NDMA exposure. [7]

The standard monitoring protocol for patients on losartan 50-100 mg daily: serum potassium and creatinine at baseline, at 4 weeks after initiation or dose change, and then every 6-12 months in stable patients without CKD. In patients with CKD stage 3b or higher (eGFR <45 mL/min/1.73 m²), check potassium and creatinine every 3 months. [4]